Medication-Naïve Blood Pressure and Incident Cancers: Analysis of 2 Nationwide Population-Based Databases
Key result
Higher SBP in medication-naïve patients linked to up to ~22% greater risk of specific cancers.
- HR 1.04-1.22
- 95% CI 1.01-1.31
- n=1,388,331
Why the study?
Previous studies on blood pressure and cancer risk were confounded by antihypertensive medications or shared risk factors, leaving the risk associated with medication-naïve high BP unclear.
Does medication-naïve high blood pressure increase the incidence of cancers in individuals without prior cancer?
Population
1,388,331 individuals without prior cancer not taking antihypertensive medications
Comparison
Blood pressure levels (systolic and diastolic BP)
Design
Retrospective observational study
Authors
Discussion
Loading...
Member takes
Implication
Higher medication-naïve SBP may flag elevated cancer risk; leaves open causality and whether BP control alters incidence.
Study Design
Type
Observational (n=1,388,331)
Multicenter
Yes
Structured PICO
Does medication-naïve high blood pressure increase the incidence of cancers in individuals without prior cancer?
P
Population
1,388,331 individuals without a prior history of cancer and not taking antihypertensive medications, median age 45, 56.2% men.
I
Intervention
Medication-naïve blood pressure (systolic and diastolic)
O
Outcome
Incidence of 16 cancershard clinical
Main Result
Effect estimate: HR 1.04-1.22 (95% CI 1.01-1.31)
Medication-naïve higher blood pressure is associated with an increased risk of incident thyroid, esophageal, colorectal, liver, and kidney cancers.
Cite This Study
Kaneko et al. (2022) conducted an observational in Medication-naïve high blood pressure (n=1,388,331). Systolic and diastolic blood pressure (per 1-SD increase) was evaluated on 16 incident cancers (HR 1.04-1.22, 95% CI 1.01-1.31). Medication-naïve higher systolic blood pressure (per 1-SD) was associated with increased incidence of thyroid, esophageal, colorectal, liver, and kidney cancers (HRs 1.04-1.22).